{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:04:09Z","timestamp":1784570649253,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptide receptor antagonist, which has been initiated for the prophylactic treatment of migraine. However, there is no comprehensive literature to study the efficacy and safety of atogepant for the treatment of migraine. In this article, we present a meta-analysis of the available studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov were searched before October 20, 2021 for any relevant literature. Eventually, three randomized clinical trials (RCTs) with 2,466 patients were included in our study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We pooled 2,466 patients from 3 RCTs and primary\u00a0outcome was mean monthly migraine days, the secondary endpoints were monthly headache days, acute medication use days per month and\u2009\u2265\u200950% reduction in monthly migraine days, baseline to end of trials. It was found that atogepant (10\u00a0mg, 30\u00a0mg, 60\u00a0mg once a day) led to a significant reduction in monthly migraine days (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, <jats:italic>P<\/jats:italic>\u2009=\u20090.007), monthly headache days (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, <jats:italic>P<\/jats:italic>\u2009=\u20090.001), and monthly medication use days (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001, <jats:italic>P<\/jats:italic>\u2009=\u20090.0001), and an increase in the proportion of people with\u2009\u2265\u200950% reduction in monthly migraine days (<jats:italic>P<\/jats:italic>\u2009=\u20090.0008, <jats:italic>P<\/jats:italic>\u2009=\u20090.02, <jats:italic>P<\/jats:italic>\u2009=\u20090.04) in comparison with placebo. Moreover, there were no significant differences (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05) in outcomes of adverse events between atogepant and placebo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Atogepant has shown good efficacy and safety in the prophylactic treatment of migraine, and further studies are expected.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01391-2","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:03:03Z","timestamp":1643457783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Xinyu","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeya","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0845","authenticated-orcid":false,"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"10127","key":"1391_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","volume":"391","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) Migraine. The Lancet 391(10127):1315\u20131330","journal-title":"The Lancet"},{"issue":"5","key":"1391_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL et al (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 18(5):459\u2013480","journal-title":"The Lancet Neurology"},{"issue":"10258","key":"1391_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T et al (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 396(10258):1204\u20131222","journal-title":"The Lancet"},{"issue":"8","key":"1391_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10194-012-0482-1","volume":"13","author":"A Raggi","year":"2012","unstructured":"Raggi A et al (2012) A systematic review of the psychosocial difficulties relevant to patients with migraine. J Headache Pain 13(8):595\u2013606","journal-title":"J Headache Pain"},{"issue":"8","key":"1391_CR5","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","volume":"260","author":"DC Buse","year":"2013","unstructured":"Buse DC et al (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260(8):1960\u20131969","journal-title":"J Neurol"},{"key":"1391_CR6","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 2018. 38(1): p. 1\u2013211","DOI":"10.1177\/0333102417738202"},{"issue":"Suppl","key":"1391_CR7","first-page":"2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache 55(Suppl):2","journal-title":"Headache"},{"issue":"23","key":"1391_CR8","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2021.7939","volume":"325","author":"JH VanderPluym","year":"2021","unstructured":"VanderPluym JH et al (2021) Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA 325(23):2357\u20132369","journal-title":"JAMA"},{"issue":"1","key":"1391_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11916-010-0165-z","volume":"15","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Kulthia A, Barrodale PM (2011) Mechanism of Chronic Migraine. Curr Pain Headache Rep 15(1):57\u201363","journal-title":"Curr Pain Headache Rep"},{"issue":"17","key":"1391_CR10","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD et al (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17):1337\u20131345","journal-title":"Neurology"},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fneur.2017.00624","volume":"8","author":"A Cascio Rizzo","year":"2017","unstructured":"Cascio Rizzo A et al (2017) Daith Piercing in a Case of Chronic Migraine: A Possible Vagal Modulation. Front Neurol 8:624","journal-title":"Front Neurol"},{"issue":"3","key":"1391_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/head.13754","volume":"60","author":"PK Winner","year":"2020","unstructured":"Winner PK et al (2020) A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. Headache 60(3):564\u2013575","journal-title":"Headache"},{"issue":"2","key":"1391_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ et al (2017) Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 97(2):553\u2013622","journal-title":"Physiol Rev"},{"issue":"Suppl 2","key":"1391_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/head.13583","volume":"59","author":"H Yuan","year":"2019","unstructured":"Yuan H, Spare NM, Silberstein SD (2019) Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache 59(Suppl 2):20\u201332","journal-title":"Headache"},{"issue":"4","key":"1391_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S et al (2019) Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety. Drugs 79(4):417\u2013431","journal-title":"Drugs"},{"key":"1391_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fneur.2020.00435","volume":"11","author":"B Gao","year":"2020","unstructured":"Gao B et al (2020) Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials. Front Neurol 11:435","journal-title":"Front Neurol"},{"issue":"8","key":"1391_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14712598.2019.1627323","volume":"19","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Cohen JM, Yeung PP (2019) Fremanezumab for the preventive treatment of migraine. Expert Opin Biol Ther 19(8):763\u2013771","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1391_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/pmt-2020-0030","volume":"11","author":"LM Frerichs","year":"2021","unstructured":"Frerichs LM, Friedman DI (2021) Galcanezumab for the prevention of migraine. Pain management 11(2):101\u2013112","journal-title":"Pain management"},{"issue":"7","key":"1391_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40265-020-01300-4","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Eptinezumab: First Approval. Drugs 80(7):733\u2013739","journal-title":"Drugs"},{"key":"1391_CR20","unstructured":"Lundbeck. Vyepti (eptinezumab-jjmr): US prescribing Information. 2020. https :\/\/ www.lundb eck.com\/uploa d\/us\/files \/pdf\/Produ cts\/Vyept i_PI_US_EN.pdf. Accessed 5 Mar 2020."},{"issue":"6","key":"1391_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14737175.2020.1772758","volume":"20","author":"E De Matteis","year":"2020","unstructured":"De Matteis E et al (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 20(6):627\u2013641","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"1391_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/head.13791","volume":"60","author":"D Tepper","year":"2020","unstructured":"Tepper D (2020) Gepants. Headache 60(5):1037\u20131039","journal-title":"Headache"},{"issue":"1","key":"1391_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","volume":"82","author":"E.D Deeks","year":"2021","unstructured":"Deeks E.D (2021) Atogepant: First Approval. Drugs 82(1):65\u201370","journal-title":"Drugs"},{"issue":"11","key":"1391_CR24","first-page":"E10","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial (vol 19, pg 727, 2020). Lancet Neurol 19(11):E10\u2013E10","journal-title":"Lancet Neurol"},{"issue":"8","key":"1391_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J et al (2021) Atogepant for the Preventive Treatment of Migraine. N Engl J Med 385(8):695\u2013706","journal-title":"N Engl J Med"},{"issue":"1S","key":"1391_CR26","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.chest.2020.03.003","volume":"158","author":"A.V Hernandez","year":"2020","unstructured":"Hernandez A.V, Marti K.M, Roman Y.M (2020) Meta-Analysis. Chest 158(1S):S97\u2013S102","journal-title":"Chest"},{"issue":"10","key":"1391_CR27","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC et al (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044","journal-title":"Cephalalgia"},{"issue":"9","key":"1391_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcph.1610","volume":"60","author":"W Ankrom","year":"2020","unstructured":"Ankrom W et al (2020) Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol\/Levonorgestrel Oral Contraceptive in Healthy Female Participants. J Clin Pharmacol 60(9):1157\u20131165","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1391_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW (2019) CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia 39(3):445\u2013458","journal-title":"Cephalalgia"},{"issue":"3","key":"1391_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0333102417741297","volume":"39","author":"S Khan","year":"2019","unstructured":"Khan S, Olesen A, Ashina M (2019) CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia 39(3):374\u2013389","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"1391_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/head.13305","volume":"58","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L (2018) The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache 58(Suppl 1):33\u201347","journal-title":"Headache"},{"issue":"9","key":"1391_CR32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1177\/0333102419829007","volume":"39","author":"D Xu","year":"2019","unstructured":"Xu D et al (2019) Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia 39(9):1164\u20131179","journal-title":"Cephalalgia"},{"issue":"6","key":"1391_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P (2019) Gepants for the treatment of migraine. Expert Opin Investig Drugs 28(6):555\u2013567","journal-title":"Expert Opin Investig Drugs"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01391-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:03:14Z","timestamp":1643457794000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01391-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01391-2","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval was not required for this type of study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors state that there are no competing interests between them.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"19"}}